SV

Street Verdict

Analyst Scorecard

AARTIPHARM · NSE

Aarti Pharmalabs Limited

₹990.7

-3.31% (-₹33.9)

Prev. close

₹1,024.6

Volume

3,49,082

Delivery %

50.8%

As of

20 Nov 2026

Price history

₹990.7+₹116.15 (+13.28%) · 3M
18 Aug 2026 → 20 Nov 2026
8008509009501,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Aarti Pharmalabs Limited

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates, such as xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. It serves pharmaceutical, nutraceutical, and beverage industries. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Rashesh Chandrakant Gogri

Headquarters

Mumbai

Employees

2,421

Key stats

Market cap

₹8,401.49 Cr

P/E ratio (TTM)

32.8

Dividend yield

0.43%

EPS (TTM)

₹28.29

Beta (1Y · daily vs NIFTY 50)

1.20

Beta (5Y · monthly vs NIFTY 50)

0.75

Shares float

4.99 Cr

EPS · quarter ended Sept 2026

₹7.87

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%5%10%15%FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Revenue for FY25 and FY26: the figure the company printed, which its own totals confirm and the series' figure did not. Revenue for FY22: from the company's own statements, which the series had none for.

02 · Earnings Per Share (EPS)

010203040₹FY22FY23FY24FY25FY26

FY22: the EPS the company printed, added because it is on the same share count as the other years.

03 · Dividend Profile

0123₹0%25%50%75%16 Feb 2431 Jul 2414 Feb 2515 Sept 2516 Feb 2615 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹1,202.46 Cr₹1,947.55 Cr₹1,857.50 Cr₹2,123.50 Cr₹1,829.19 Cr
₹1,047.08 Cr₹1,686.78 Cr₹1,557.01 Cr₹1,762.81 Cr₹1,601.47 Cr
Profit before share of profit/ (loss) of joint ventures, exceptional
———₹360.69 Cr₹227.72 Cr
Share of profit/(loss) of joint ventures
————₹8.00 Cr
Profit before exceptional items and tax (3+4)
₹155.38 Cr₹260.77 Cr₹300.49 Cr₹360.69 Cr₹235.72 Cr
Exceptional Items gain/(Loss)
————₹-2.79 Cr
Profit before tax (5+6)
₹155.38 Cr₹260.77 Cr₹300.49 Cr₹360.69 Cr₹232.92 Cr
(a) Current Tax
₹27.33 Cr₹55.98 Cr₹58.84 Cr₹72.20 Cr₹43.05 Cr
MAT Credit Entitlement
₹1.13 Cr————
(b) Earlier Year Tax
—₹3.13 Cr₹-3.06 Cr₹-4.70 Cr₹-88.06 L
(c) Deferred Tax
₹4.68 Cr₹8.17 Cr₹27.82 Cr₹20.78 Cr₹16.05 Cr
Total Tax Expenses (a to c)
₹33.13 Cr₹67.28 Cr₹83.59 Cr₹88.28 Cr₹58.21 Cr
Profit for the year (7-8)
₹122.25 Cr₹193.49 Cr₹216.90 Cr₹272.40 Cr₹174.71 Cr
₹129.32 Cr₹190.05 Cr₹216.45 Cr₹262.65 Cr₹168.47 Cr
Basic
13.4921.3523.9330.0619.27
Diluted
13.4921.3523.9330.0419.25

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹2,039.90 Cr₹2,244.02 Cr₹2,582.11 Cr₹2,902.43 Cr₹3,481.71 Cr
₹1,011.75 Cr₹1,081.02 Cr₹1,236.46 Cr₹1,584.24 Cr₹2,084.41 Cr
₹1,028.15 Cr₹1,163.01 Cr₹1,345.64 Cr₹1,318.19 Cr₹1,397.29 Cr
₹1,386.48 Cr₹1,558.49 Cr₹1,757.04 Cr₹1,989.91 Cr₹2,124.60 Cr
(a) Equity Share Capital
₹25.00 L₹45.31 Cr₹45.31 Cr₹45.32 Cr₹45.33 Cr
Equity Share Capital pending allotment upon scheme of arrangment
₹45.31 Cr————
(b) Other Equity
₹1,340.92 Cr₹1,513.17 Cr₹1,711.73 Cr₹1,944.59 Cr₹2,079.28 Cr
₹653.42 Cr₹685.54 Cr₹825.07 Cr₹912.52 Cr₹1,357.10 Cr
₹72.76 Cr₹84.91 Cr₹130.68 Cr₹259.45 Cr₹419.53 Cr
₹580.66 Cr₹600.62 Cr₹694.39 Cr₹653.07 Cr₹937.57 Cr
TOTAL EQUITY AND LIBILITIES (I+II+III)
₹2,039.90 Cr₹2,244.02 Cr₹2,582.11 Cr₹2,902.43 Cr₹3,481.71 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY23FY24FY25FY26
₹-71.15 Cr₹11.51 Cr₹-16.90 Cr₹1.80 Cr
₹250.12 Cr₹216.35 Cr₹330.14 Cr₹261.93 Cr
₹-157.80 Cr₹-214.56 Cr₹-412.48 Cr₹-430.72 Cr
₹-163.46 Cr₹9.72 Cr₹65.43 Cr₹170.58 Cr
Cash and Cash Equivalent at the beginning of the year
—₹12.12 Cr——
Opening Balance of Cash and Cash Equivalents
₹83.27 Cr—₹23.63 Cr₹6.73 Cr
Closing Balance of Cash and Cash Equivalents
₹12.12 Cr₹23.63 Cr₹6.73 Cr₹8.53 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemJan 23Mar 23–Jun 23(2Q)Sep 23Dec 23–Jun 24(3Q)Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Promoter44.16%45.98%46.30%46.46%46.10%44.66%44.29%43.72%42.88%43.10%43.08%42.86%
Public55.84%54.02%53.70%53.54%53.90%55.34%55.71%56.28%57.12%56.90%56.92%57.14%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Aarti Pharmalabs Limited₹8,342.09 Cr₹926.532.53.938.2%0.36-14.3%+9.7%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Index membership

2 indices

AARTIPHARM

Aarti Pharmalabs rises 2.95% in Tuesday's session

Global Banking & Finance Review · 5 days ago

AARTIPHARM

Aarti Pharmalabs targets 8,800 tonnes, pauses xanthine expansion

Multibagg AI · 18 days ago